Author: nellyblakemore

AIM Vaccine Co., Ltd. (“AIM Vaccine” or the “Company”, together with its subsidiaries, the “Group”, stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) today, with a board lot of 200 H shares each. The debut of AIM Vaccine’s stock price was very outstanding on 6 October. The share price closed at HK$16.66, up 3.09%. Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities ... Read more